Boston, MA 10/07/2014 (wallstreetpr) – Pharma firm Alcobra Ltd (NASDAQ:ADHD) announced on 6th October that its phase three tests on its drug candidate Metadoxine to treat Attention Deficit Hyperactivity Disorder. The drug maker announced that the results have indicated that the “extended release” approach of administering the drug to adults which is being experimented has showed positive results. Following the announcement, Alcobra Ltd (NASDAQ:ADHD) President and Chief Executive Officer announced that his R&D team will derive encouragement from the findings. He further expressed happiness that the study did not get embroiled in “safety and tolerability issues” that such tests generally run into during clinical trials.
Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR) saw a huge slide in its share price during trading on 6th October after analysts at rating house Leerink downgraded the stock. The new rating has been pegged at market perform from previous recommendation of outperform. The downgrade comes even as the company stock has been gaining on the back of the huge potential the drug maker would enjoy in the event of its test drug designed to treat the dreaded Ebola virus gets approved. The company stock had sky rocketed over the past 60 days after it emerged that its test drug had been used to treat one of the compromised American patient.
RadioShack Corporation (NYSE:RSH) stock saw a double digit percentage slide yesterday after investors and analysts alike, discounted the likely long term positive impact of the financing package the electronics retailer announced last week. The analysts have pointed out that the short term debt raised by the retailer from one of its existing customer is more likely going to be a stop gap arrangement, rather than a long lasting solution for the cash flow problems RadioShack Corporation (NYSE:RSH) is facing. Standard General LP which has emerged as one of the biggest investors in the embattled firm had last week announced that it is refinancing a $535 million loan in order to help the firm meet its immediate debt burden.